Triple-negative breast cancers (TNBC), i.e., tumors negative for ER, PR and HER2, comprise 15–20% of breast cancers in the United States but account for a disproportionate share of morbidity and mortality (Boyle 2012). Here, ERBB2 is linked to breast cancer.